Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions

US10568972B2 · kind B2 · utility

Assignee

• CureVac AG · DE

Inventors

• Florian Von Der Mülbe · Stuttgart, DE
• Ingmar Hoerr · Tübingen, DE
• Steve Pascolo · Tübingen, DE

Key dates

• Filing date: Jan 25, 2016
• Grant date: Feb 25, 2020
• Expiry date: Dec 30, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.